吸收不良综合征市场（2026—2031）
吸收不良综合征市场规模预计由2026年的40.2亿美元增至2031年的54.6亿美元，预测期复合年增长率为6.32%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
吸收不良综合征市场规模预计由2026年的40.2亿美元增至2031年的54.6亿美元，预测期复合年增长率为6.32%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 6.32% | 机构预测 |
| 市场规模 | 2026 | USD 4.02 billion | 机构预测 |
| 市场规模 | 2031 | USD 5.46 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease | celiac disease | 2025 | 34.700% |
| distribution_channel | hospital pharmacies | 2025 | 44.200% |
| end_user | hospitals | 2025 | 46.500% |
| geography | North America | 2025 | 40.800% |
| offering | the treatment segment | 2025 | 61.800% |
| route_of_administration | oral administration | 2025 | 72.400% |
关键结论
- disease 维度中，celiac disease 在 2025 年的公开份额为 34.7%。
- distribution_channel 维度中，hospital pharmacies 在 2025 年的公开份额为 44.2%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 46.5%。
- geography 维度中，North America 在 2025 年的公开份额为 40.8%。
- offering 维度中，the treatment segment 在 2025 年的公开份额为 61.8%。
- route_of_administration 维度中，oral administration 在 2025 年的公开份额为 72.4%。
主要参与者
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Nestlé Health Science
- Abbott Laboratories
- Fresenius Kabi AG
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Prevalence of Gastrointestinal and Pancreatic Disorders | +1.800% | Global, concentrated in Asia-Pacific and North America | Long term (≥ 4 years) |
| Broader Screening and Diagnostic Access | +1.400% | Europe, North America, with spillover to core Asia-Pacific countries | Medium term (2-4 years) |
| Expansion of Clinical Nutrition and Enzyme Replacement | +1.200% | Global, with highest adoption in North America and Europe | Medium term (2-4 years) |
| Aging and Pediatric High-Risk Populations | +0.900% | Japan, Germany, North America, and core Asia-Pacific countries | Long term (≥ 4 years) |
| Reimbursement-Linked Shift to Home Nutrition and Remote Adherence | +0.700% | North America and Europe | Medium term (2-4 years) |
| Microbiome and Organoid-Enabled Precision Malabsorption Care | +0.500% | North America and Europe | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High Therapy and Diagnostic Costs With Uneven Reimbursement | -1.600% | North America and Europe | Short term (≤ 2 years) |
| Underdiagnosis and Nonstandardized Diagnostic Pathways | -1.200% | Global, particularly Asia-Pacific and the Middle East and Africa | Long term (≥ 4 years) |
| Fragmented Etiology Diluting Commercial Treatment Endpoints | -0.800% | Global | Long term (≥ 4 years) |
| Dietary Adherence and Cross-Contamination Confounding Clinical Outcomes | -0.600% | Global, with higher intensity in Europe and North America | Medium term (2-4 years) |
报告关注的关键问题
What is the projected value of the malabsorption syndrome market by 2031?
The malabsorption syndrome market is forecast to reach USD 5.46 billion by 2031, expanding at a 7.12% CAGR from 2026. Growth reflects broader diagnosis and treatment needs across celiac disease, inflammatory bowel disease, pancreatic insufficiency, and intestinal failure. Hospital treatment, home nutrition support, and specialized pharmacy services each support the forecast. The forecast also reflects wider use of pancreatic enzyme replacement therapy and more structured nutrition monitoring. Care models increasingly connect hospital treatment with home-based supply services for patients who need sustained support.
Which disease category leads malabsorption syndrome care?
Celiac disease led with a 34.70% share in 2025. Its large position reflects a broad patient base, established dietary management needs, and a substantial group of patients who remain undiagnosed in many countries. Clinical screening and validated serological tests are important for bringing more patients into care.
Which malabsorption syndrome treatment area is growing fastest?
Short bowel syndrome and intestinal failure is forecast to expand at an 8.90% CAGR through 2031. Growth is supported by GLP-2 therapy development, pediatric survival gains, and demand for treatment options that reduce parenteral nutrition dependence. Oral and less frequent subcutaneous therapies may improve treatment convenience for eligible patients.
Why are diagnostic services becoming more important for celiac disease?
European guidance allows a conditional biopsy-free diagnosis route for selected adults. This may reduce access barriers, while the low rate of confirmed diagnoses in France and continuing diagnostic delays in Germany leave many patients outside formal care pathways. Providers must still align test pathways with local clinical guidance.
Which distribution channel is forecast to grow fastest for malabsorption therapies?
Online pharmacies are forecast to grow at a 10.20% CAGR through 2031. Digital prescription fulfillment, telehealth links, and cold-chain home delivery can make recurring supplies easier to access for patients receiving chronic gastrointestinal treatment. Their adoption depends on reimbursement, dependable delivery, and ongoing pharmacist support.
What limits the growth of home nutrition support?
Rising home parenteral nutrition preparation costs, declining reimbursement, ingredient shortages, and documentation requirements limit provider capacity. These pressures can favor hospital-based services when independent home infusion suppliers cannot recover the full cost of care. Payment policies and supplier sustainability remain important for patient access.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：低
查看来源：Mordor Intelligence